XML 28 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Long-Term Debt And Lines Of Credit
 12 Months Ended
Dec. 31, 2021
Long-Term Debt And Lines Of Credit [Abstract]  
Long-Term Debt And Lines Of Credit 3.    Long-Term Debt and Lines of Credit On June 20, 2018, we replaced our existing credit agreement with the Fourth Amended and Restated Credit Agreement (“2018 Credit Agreement”). Terms of the 2018 Credit Agreement consist of a five year, $450 million revolving credit facility and a $150 million expansion feature, which may consist of term loans or additional revolving commitments. The 2018 Credit Agreement has a floating interest rate that is generally LIBOR plus a tiered additional rate which varies based on our current leverage ratio. For December 31, 2021 and 2020, respectively, the interest rate is LIBOR plus 100 basis points. The 2018 Credit Agreement includes transition provisions in the instance LIBOR is no longer published or used as an industry-accepted rate. Any amounts outstanding under the 2018 Credit Agreement at its June 20, 2023 maturity date will be immediately due and payable. Debt issuance costs associated with the prior credit agreement were not written off as the lenders and their relative percentage participation in the facility did not change. With respect to the 2018 Credit Agreement, deferred financing costs were $1.0 million. The debt outstanding at December 31, 2021 and 2020 consists of the following (in thousands): December 31, 2021 2020Revolver$ 185,000 $ -Term loan - -Total 185,000 -Current portion - -Long-term debt$ 185,000 $ - Capitalized interest was not material for any of the periods shown. Summarized below are the total amounts of interest paid during the years ended December 31 (in thousands): 2021$1,4032020 2,0282019 4,125 The 2018 Credit Agreement contains the following quarterly financial covenants effective as of December 31, 2021: ChemedDescription Requirement December 31, 2021 Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) < 3.50 to 1.00 0.52 to 1.00 Fixed Charge Coverage Ratio (Consolidated Free Cash Flow/Consolidated Fixed Charges) > 1.50 to 1.00 3.12 to 1.00 We are in compliance with all debt covenants as of December 31, 2021. We have issued $46.2 million in standby letters of credit as of December 31, 2021 for insurance purposes. Issued letters of credit reduce our available credit under the 2018 Credit Agreement. As of December 31, 2021, we have approximately $218.8 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility.